Literature DB >> 34950512

Targeted drug delivery strategies for precision medicines.

Mandana T Manzari1,2, Yosi Shamay3,2, Hiroto Kiguchi4,5,2, Neal Rosen6,7,8, Maurizio Scaltriti8,9, Daniel A Heller1,7.   

Abstract

Progress in the field of precision medicine has changed the landscape of cancer therapy. Precision medicine is propelled by technologies that enable molecular profiling, genomic analysis, and optimized drug design to tailor treatments for individual patients. Although precision medicines have resulted in some clinical successes, the use of many potential therapeutics has been hindered by pharmacological issues, including toxicities and drug resistance. Drug delivery materials and approaches have now advanced to a point where they can enable the modulation of a drug's pharmacological parameters without compromising the desired effect on molecular targets. Specifically, they can modulate a drug's pharmacokinetics, stability, absorption, and exposure to tumours and healthy tissues, and facilitate the administration of synergistic drug combinations. This Review highlights recent progress in precision therapeutics and drug delivery, and identifies opportunities for strategies to improve the therapeutic index of cancer drugs, and consequently, clinical outcomes.

Entities:  

Year:  2021        PMID: 34950512      PMCID: PMC8691416          DOI: 10.1038/s41578-020-00269-6

Source DB:  PubMed          Journal:  Nat Rev Mater        ISSN: 2058-8437            Impact factor:   66.308


  313 in total

Review 1.  Polymers for gene delivery across length scales.

Authors:  David Putnam
Journal:  Nat Mater       Date:  2006-06       Impact factor: 43.841

2.  ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?

Authors:  Inna Smalley; Keiran S M Smalley
Journal:  Cancer Discov       Date:  2018-02       Impact factor: 39.397

3.  Probing the self-assembly mechanism of diphenylalanine-based peptide nanovesicles and nanotubes.

Authors:  Cong Guo; Yin Luo; Ruhong Zhou; Guanghong Wei
Journal:  ACS Nano       Date:  2012-04-09       Impact factor: 15.881

Review 4.  Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.

Authors:  Alberto Gabizon; Hilary Shmeeda; Yechezkel Barenholz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

Authors:  Zachary S Zumsteg; Natasha Morse; Gabriel Krigsfeld; Gaorav Gupta; Daniel S Higginson; Nancy Y Lee; Luc Morris; Ian Ganly; Stephan L Shiao; Simon N Powell; Christine H Chung; Maurizio Scaltriti; José Baselga
Journal:  Clin Cancer Res       Date:  2015-11-20       Impact factor: 12.531

6.  A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.

Authors:  R Plummer; R H Wilson; H Calvert; A V Boddy; M Griffin; J Sludden; M J Tilby; M Eatock; D G Pearson; C J Ottley; Y Matsumura; K Kataoka; T Nishiya
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

Review 7.  Management of adverse events associated with idelalisib treatment: expert panel opinion.

Authors:  Steven E Coutré; Jacqueline C Barrientos; Jennifer R Brown; Sven de Vos; Richard R Furman; Michael J Keating; Daniel Li; Susan M O'Brien; John M Pagel; Martin H Poleski; Jeff P Sharman; Nai-Shun Yao; Andrew D Zelenetz
Journal:  Leuk Lymphoma       Date:  2015-05-19

8.  Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity.

Authors:  Chunling Dong; Bo Li; Zhenyu Li; Sreerama Shetty; Jian Fu
Journal:  Oncotarget       Date:  2016-08-02

Review 9.  ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.

Authors:  Shundong Cang; Chaitanya Iragavarapu; John Savooji; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2015-11-20       Impact factor: 17.388

10.  Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy.

Authors:  Carlos Pérez-Medina; Dalya Abdel-Atti; Jun Tang; Yiming Zhao; Zahi A Fayad; Jason S Lewis; Willem J M Mulder; Thomas Reiner
Journal:  Nat Commun       Date:  2016-06-20       Impact factor: 14.919

View more
  24 in total

Review 1.  Current approaches of nanomedicines in the market and various stage of clinical translation.

Authors:  Xiaoting Shan; Xiang Gong; Jie Li; Jingyuan Wen; Yaping Li; Zhiwen Zhang
Journal:  Acta Pharm Sin B       Date:  2022-03-01       Impact factor: 14.903

Review 2.  Merging data curation and machine learning to improve nanomedicines.

Authors:  Chen Chen; Zvi Yaari; Elana Apfelbaum; Piotr Grodzinski; Yosi Shamay; Daniel A Heller
Journal:  Adv Drug Deliv Rev       Date:  2022-02-18       Impact factor: 17.873

3.  Evaluation of Cellular Targeting by Fab' vs Full-Length Antibodies in Antibody-Nanoparticle Conjugates (ANCs) Using CD4 T-cells.

Authors:  Khushboo Singh; Mine Canakci; Pintu Kanjilal; Natalie Williams; Sudarvili Shanthalingam; Barbara A Osborne; S Thayumanavan
Journal:  Bioconjug Chem       Date:  2022-02-09       Impact factor: 6.069

4.  Oxidative Damage Induced by Phototoxic Pheophorbide a 17-Diethylene Glycol Ester Encapsulated in PLGA Nanoparticles.

Authors:  Mariia R Mollaeva; Elena Nikolskaya; Veronika Beganovskaya; Maria Sokol; Margarita Chirkina; Sergey Obydennyi; Dmitry Belykh; Olga Startseva; Murad D Mollaev; Nikita Yabbarov
Journal:  Antioxidants (Basel)       Date:  2021-12-13

Review 5.  Advancement of Nanofibrous Mats and Common Useful Drug Delivery Applications.

Authors:  Hamza Abu Owida; Jamal I Al-Nabulsi; Feras Alnaimat; Ashraf Al Sharah; Muhammad Al-Ayyad; Nidal M Turab; Mustafa Abdullah
Journal:  Adv Pharmacol Pharm Sci       Date:  2022-04-19

Review 6.  Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and progress in drug delivery systems.

Authors:  Daniyah A Almarghalani; Sai H S Boddu; Mohammad Ali; Akhila Kondaka; Devin Ta; Rayyan A Shah; Zahoor A Shah
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

Review 7.  Nanotechnology-enhanced immunotherapy for metastatic cancer.

Authors:  Peisen Zhang; Junli Meng; Yingying Li; Chen Yang; Yi Hou; Wen Tang; Kevin J McHugh; Lihong Jing
Journal:  Innovation (Camb)       Date:  2021-10-14

Review 8.  Smart Nucleic Acid Hydrogels with High Stimuli-Responsiveness in Biomedical Fields.

Authors:  Jie Li; Yangzi Zhang; Longjiao Zhu; Keren Chen; Xiangyang Li; Wentao Xu
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

Review 9.  Multifunctional co-transport carriers based on cyclodextrin assembly for cancer synergistic therapy.

Authors:  Shouhui Yi; Rongqiang Liao; Wei Zhao; Yusheng Huang; Yi He
Journal:  Theranostics       Date:  2022-02-28       Impact factor: 11.600

Review 10.  Hollow structures as drug carriers: Recognition, response, and release.

Authors:  Decai Zhao; Nailiang Yang; Lekai Xu; Jiang Du; Yang Yang; Dan Wang
Journal:  Nano Res       Date:  2021-07-08       Impact factor: 8.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.